Quick Summary:
In the complex sphere of the global Inflammatory Bowel Disease (IBD) Therapeutics market, consistency of data, insight depth, and timely information are critical for making informed and successful decisions. Our latest report offers a robust and comprehensive analysis of this burgeoning market with projections that estimate its value to reach $32.8 Billion by 2030.
Key features of this report include an exhaustive analysis of the TNF inhibitors and Anti-integrin segments, potential growth areas, and leading geographic markets such as the U.S. and China. Our analysis is focused on helping you understand the market trajectory and future trends. You will not only gain insights into the current standings of key competitors but also understand market presence across various geographies.
Our interactive, peer-to-peer collaborative updates, coupled with access to digital archives and complimentary updates for a year, make our offering an indispensable tool for senior business executives pursuing strategic objectives in the IBD Therapeutics market. Stay ahead in this competitive landscape with our trusted, cutting-edge research.
Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach $32.8 Billion by 2030
The global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$23.2 Billion in the year 2022, is projected to reach a revised size of US$32.8 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. TNF inhibitors, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$14 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anti-integrin segment is readjusted to a revised 4.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $6.3 Billion, While China is Forecast to Grow at 8.7% CAGR
The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$6.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 8.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.Select Competitors (Total 69 Featured) -
- 4SC AG
- Abbott Nutrition
- AbbVie, Inc.
- Ablynx NV
- Active Biotech AB
- Alfasigma S.p.A.
- Allergan PLC
- Allergan PLC
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Athersys, Inc.
- Atlantic Healthcare plc
- Avaxia Biologics, Inc.
- Biosafe Systems, LLC
- Boehringer Ingelheim GmbH
- Cadila Healthcare Ltd.
- Celgene Corporation
- Celltrion, Inc.
- Cipla Ltd.
- Coherus Biosciences, Inc.
- Cosmo Pharmaceuticals NV
- Dr. Falk Pharma GmbH
- EA Pharma Co., Ltd.
- Eddingpharm
- EPIRUS Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- F. Hoffmann-La Roche AG
- Galapagos NV
- Giaconda Ltd.
- Google LLC
- Immunic, Inc.
- InDex Pharmaceuticals Holding AB
- Infinity Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- LG Sciences
- Lupin Ltd.
- Mochida Pharmaceutical Co., Ltd.
- Mylan Pharmaceutical Pvt. Ltd.
- Neovacs SA
- Nogra Pharma Limited
- NovaMedica LLC
- Novartis International AG
- Osiris Therapeutics, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- PAR Pharmaceutical Companies, Inc.
- PendoPharm, Inc.
- Perrigo Company PLC
- Pfenex, Inc.
- Pfizer, Inc.
- Pharmascience Inc.
- Pluristem Therapeutics, Inc.
- Qu Biologics Inc.
- Quest Diagnostics, Inc.
- RedHill Biopharma Ltd.
- Reliance Life Sciences
- Salix Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi
- Sequella, Inc.
- Soligenix, Inc.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Toray Industries, Inc.
- Torrent Pharmaceuticals Ltd.
- UCB SA
- Zeria Pharmaceutical Co., Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Inflammatory Bowel Disease (IBD) Therapeutics
What is the estimated value of the Global Market for Inflammatory Bowel Disease (IBD) Therapeutics?
What is the growth rate of the Global Market for Inflammatory Bowel Disease (IBD) Therapeutics?
What is the forecasted size of the Global Market for Inflammatory Bowel Disease (IBD) Therapeutics?
Who are the key companies in the Global Market for Inflammatory Bowel Disease (IBD) Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 146 |
| Published | December 2023 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 20.6 Billion |
| Forecasted Market Value ( USD | $ 27.9 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
A selection of companies mentioned in this report includes:
- 4SC AG
- Abbott Nutrition
- AbbVie, Inc.
- Ablynx NV
- Active Biotech AB
- Alfasigma S.p.A.
- Allergan PLC
- Allergan PLC
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Athersys, Inc.
- Atlantic Healthcare plc
- Avaxia Biologics, Inc.
- Biosafe Systems, LLC
- Boehringer Ingelheim GmbH
- Cadila Healthcare Ltd.
- Celgene Corporation
- Celltrion, Inc.
- Cipla Ltd.
- Coherus Biosciences, Inc.
- Cosmo Pharmaceuticals NV
- Dr. Falk Pharma GmbH
- EA Pharma Co., Ltd.
- Eddingpharm
- EPIRUS Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche AG
- F. Hoffmann-La Roche AG
- Galapagos NV
- Giaconda Ltd.
- Google LLC
- Immunic, Inc.
- InDex Pharmaceuticals Holding AB
- Infinity Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- LG Sciences
- Lupin Ltd.
- Mochida Pharmaceutical Co., Ltd.
- Mylan Pharmaceutical Pvt. Ltd.
- Neovacs SA
- Nogra Pharma Limited
- NovaMedica LLC
- Novartis International AG
- Osiris Therapeutics, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- PAR Pharmaceutical Companies, Inc.
- PendoPharm, Inc.
- Perrigo Company PLC
- Pfenex, Inc.
- Pfizer, Inc.
- Pharmascience Inc.
- Pluristem Therapeutics, Inc.
- Qu Biologics Inc.
- Quest Diagnostics, Inc.
- RedHill Biopharma Ltd.
- Reliance Life Sciences
- Salix Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi
- Sequella, Inc.
- Soligenix, Inc.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Toray Industries, Inc.
- Torrent Pharmaceuticals Ltd.
- UCB SA
- Zeria Pharmaceutical Co., Ltd.
